Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
Homologous recombination deficiency testing and molecular profiling are reshaping treatment strategies for advanced ovarian cancer, guiding PARP inhibitor and bevacizumab maintenance decisions in newly diagnosed patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07702292 |
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications |
RECRUITING | PHASE2 |
| NCT07674615 |
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07617753 |
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 |
RECRUITING | PHASE1/PHASE2 |
| NCT07545460 |
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07432633 |
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications |
RECRUITING | PHASE1/PHASE2 |
| NCT07303894 |
A Study of Isoquercetin in People With Ovarian Cancer |
RECRUITING | PHASE2 |
| NCT07218809 |
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer |
RECRUITING | PHASE3 |
| NCT07075939 |
Centralization and Oncologic Outcomes in Ovarian Cancer |
RECRUITING | |
| NCT06994195 |
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) |
RECRUITING | PHASE3 |
| NCT06915025 |
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
RECRUITING | PHASE3 |
